Amarin Co. plc (NASDAQ:AMRN) Forecasted to Post FY2027 Earnings of $0.20 Per Share

Amarin Co. plc (NASDAQ:AMRNFree Report) – Leerink Partnrs issued their FY2027 earnings per share estimates for Amarin in a research note issued on Monday, February 5th. Leerink Partnrs analyst R. Ruiz expects that the biopharmaceutical company will post earnings per share of $0.20 for the year. The consensus estimate for Amarin’s current full-year earnings is ($0.19) per share.

Several other brokerages have also commented on AMRN. Cantor Fitzgerald reissued an “overweight” rating on shares of Amarin in a research report on Friday, January 12th. Jefferies Financial Group lowered Amarin from a “buy” rating to a “hold” rating and lowered their price objective for the company from $3.00 to $1.00 in a research report on Wednesday, October 25th. Finally, JPMorgan Chase & Co. restated an “underweight” rating on shares of Amarin in a report on Monday, November 20th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, Amarin has an average rating of “Hold” and a consensus target price of $1.08.

Check Out Our Latest Report on AMRN

Amarin Stock Up 2.5 %

Shares of AMRN stock opened at $1.23 on Wednesday. The stock has a fifty day moving average of $1.00 and a 200 day moving average of $0.95. Amarin has a 52 week low of $0.65 and a 52 week high of $2.17. The firm has a market capitalization of $496.71 million, a price-to-earnings ratio of -9.46 and a beta of 2.05.

Insider Activity

In related news, insider Steven B. Ketchum sold 34,131 shares of Amarin stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $0.79, for a total value of $26,963.49. Following the completion of the sale, the insider now directly owns 566,100 shares in the company, valued at approximately $447,219. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 8.81% of the company’s stock.

Institutional Investors Weigh In On Amarin

Several large investors have recently bought and sold shares of AMRN. Hayek Kallen Investment Management boosted its position in Amarin by 63.3% in the fourth quarter. Hayek Kallen Investment Management now owns 1,016,760 shares of the biopharmaceutical company’s stock worth $885,000 after purchasing an additional 394,117 shares during the last quarter. Vanguard Personalized Indexing Management LLC boosted its position in Amarin by 100.6% in the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 46,480 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 23,313 shares during the last quarter. BNP Paribas Financial Markets boosted its position in Amarin by 705.2% in the fourth quarter. BNP Paribas Financial Markets now owns 455,177 shares of the biopharmaceutical company’s stock worth $396,000 after purchasing an additional 398,648 shares during the last quarter. LCM Capital Management Inc boosted its position in Amarin by 5.1% in the fourth quarter. LCM Capital Management Inc now owns 740,159 shares of the biopharmaceutical company’s stock worth $644,000 after purchasing an additional 36,000 shares during the last quarter. Finally, Gilliland Jeter Wealth Management LLC purchased a new position in Amarin in the fourth quarter worth about $64,000. 25.51% of the stock is currently owned by institutional investors.

Amarin Company Profile

(Get Free Report)

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.

Featured Articles

Earnings History and Estimates for Amarin (NASDAQ:AMRN)

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.